Hansoh Pharma reports 11.71 percent revenue growth for Hansoh Pharma stock

Published on 10/15/2026 at 21:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half profit rose 35.82 percent on August 26, 2026. Hansoh Pharma stock costs EUR 3.54 on October 15, 2026, up 2.62 percent on the Hong Kong Stock Exchange.

Revenue and valuation details

On August 26, 2026, Hansoh Pharma reported 11.71 percent first-half revenue growth.
First-half profit attributable to shareholders increased 35.82 percent year over year.
Hansoh Pharma stock costs EUR 3.54 at Lang & Schwarz on October 15, 2026 at 9:21 p.m. CEST, up 2.62 percent on the Hong Kong Stock Exchange.
Hansoh Pharma had a P/E ratio of 24.55 and market capitalization of HKD 190.2 billion on October 15, 2026.

Hansoh Pharma, KYG549581067, Illustration mit AI erstellt.

Hansoh Pharma reported revenue of RMB 8.304 billion for the six months ended June 30, 2026, up 11.71 percent year over year, according to GMT Eight on August 26, 2026. The company also posted RMB 4.258 billion in profit attributable to shareholders, an increase of 35.82 percent. Hansoh Pharma stock was priced at EUR 3.54 at Lang & Schwarz on October 15, 2026 at 9:21 p.m. CEST.

Profit growth outpaced revenue

The first-half figures show a wider profit increase than revenue growth. GMT Eight reported earnings per share of RMB 0.70 for the period and said the profit increase was primarily linked to higher innovative-drug revenue and other income.

The Hong Kong range remains wide

Hansoh's Hong Kong-listed shares closed at HKD 31.38 on October 15, 2026, up 2.62 percent from HKD 30.58. The quote stood 29.04 percent below its 52-week high of HKD 44.22 and 11.83 percent above its 52-week low of HKD 28.06. Trading volume reached 10,475,925 shares, compared with an average volume of 10,397,329.

Valuation and pipeline scale

Hansoh Pharma had a market capitalization of HKD 190.2 billion and a P/E ratio of 24.55 on October 15, 2026. Its website describes the company as a China-based drugmaker focused on oncology, metabolism, immunology, central nervous system treatments and anti-infectives, with seven marketed innovative drugs and more than 30 innovative drug programs.

Comparison with peers

Hansoh Pharma (Hong Kong Stock Exchange, HKD): up 2.62 percent, P/E 24.55, market capitalization HKD 190.2 billion.

CSPC Pharmaceutical Group (Hong Kong Stock Exchange, HKD): up 0.62 percent, P/E 11.63, market capitalization HKD 101.1 billion.

Sino Biopharmaceutical (Hong Kong Stock Exchange, HKD): up 2.03 percent, P/E 33.99, market capitalization HKD 93.9 billion.

Price position for investors

The contrast is clear: Hansoh traded closer to its yearly low than its yearly high, while its P/E ratio stood above CSPC Pharmaceutical Group's but below Sino Biopharmaceutical's. The company said more than 80 percent of revenue comes from innovative drugs and collaborative products.

The further course of trading is shown by the continuously updated real-time quote of Hansoh Pharma stock.